The veterinary-grade Yinqiao Banlangen powder is processed as a water-extracted herbal input material intended for conversion into non-sterile oral solid dosage forms, drinking-water formulations, feed premixes, and, after pyrogen-controlled refinement, sterile injectable solutions. Specification parameters commonly applied at release include loss on drying ≤5.0%, total ash ≤8.0%, heavy-metal limits of Pb ≤5 mg/kg, Cd ≤1 mg/kg, As ≤2 mg/kg, and Hg ≤0.1 mg/kg, with microbiological acceptance criteria of ≤1000 CFU/g aerobic plate count, ≤100 CFU/g yeast and mould, absence of Escherichia coli in 1 g, and absence of Salmonella in 25 g. These limits are aligned with non-sterile oral material monographs in the Chinese Veterinary Pharmacopoeia 2020 and are cross-checked against USP <795> where extemporaneous compounding applies. Aqueous dispersibility is pH-dependent: in deionized water at 25°C, the powder forms a turbid solution with solubility commonly observed in the range of 25–35 g/L, but below pH 4.0 flavonoid aglycone precipitation may occlude proportioner screens and drinking-line filters. The downstream applications are separated into six processing routes based on dosage form, target species, and hygienic class.

In high-density grower-finisher barns where porcine reproductive and respiratory syndrome virus, swine influenza A virus, and secondary bacterial fever events overlap, the powder is most frequently converted into a water-soluble oral powder or a micro-ingredient premix for drinking-water medication. The industry compliance framework for this route is governed by Regulation (EU) 2019/6 where the finished product is registered as a veterinary medicinal product, and by Regulation (EU) 2019/4 where it is used as a medicated feed premix; in China, the applicable Chinese Veterinary Pharmacopoeia 2020 monograph and Ministry of Agriculture and Rural Affairs formulation announcement apply. The conversion ratio used at farm level must be calculated from the authorized daily dose and the measured water-intake profile of the barn. For example, where a finishing pig consumes 4.0 L of drinking water per day and the registered intake is 1.0 g powder per 100 kg body weight, a stock solution is prepared at 100 g/L and metered through a 1:256 dosing pump to yield a final concentration of approximately 0.39 g/L; under heat stress, rising water consumption requires proportional reduction of stock concentration to avoid overdosing. Production of the water-soluble powder begins with a two-stage size-reduction step using a hammer mill fitted with an 0.8 mm screen to achieve D90 below 150 µm, because dry blending alone may not fully deagglomerate the spray-dried botanical matrix. The milled powder is then blended with anhydrous dextrose or sodium sulfate carrier in a 500 L trough ribbon blender for 10–12 min, sieved through a 40-mesh screen, and packed into 5 kg foil-lined pouches with 10 g desiccant. A documented process limit is that mill chamber temperature must remain below 45°C; above this threshold, the dried herbal matrix can plasticize, producing screen blinding and poor blend uniformity. Terminal product types for this route include 5 kg water-soluble powder sachets, 500 g farm pouches, and 0.5% w/w feed premix packed in 25 kg bags.

Does Cold-Water Dispersibility Constrain Poultry Dose Uniformity?

In broiler and layer integrations where infectious bronchitis virus and Newcastle disease virus vaccination gaps create secondary viral challenges, the powder is formulated as a cold-water-dispersible granule or oral solution for administration through closed drinking lines. The critical failure mode observed on production lines is particle-size segregation during pneumatic conveying and uneven wetting in header tanks at water temperatures below 6°C, which produces bird-level dose variability above the ±10% acceptance limit. Compliance for this route is anchored to Regulation (EU) 2019/6 pharmaceutical quality requirements for veterinary granules and to Ph. Eur. 2.9.12 flowability and Ph. Eur. 2.9.36 uniformity of mass of single-dose preparations where applicable; for export into ASEAN markets, the national veterinary authority's GMP inspection may reference PIC/S GMP Guide Annex 15 for qualification and validation. The manufacturing process selected for cold-water dispersibility is fluid-bed spray granulation, in which the milled powder is charged into a top-spray unit with inlet air at 58–62°C, product temperature held at 36–40°C, and an aqueous binder solution of 5% w/w PVP K30 sprayed at 12–15 mL/min per kg bed. After drying to a moisture content of ≤3.0%, the granulate is sieved to retain 20–80 mesh and filled into 100 g or 500 g triple-laminate sachets. The addition ratio in target drinking water is normally 0.2–0.5 g/L for 5–7 consecutive days, depending on the registered indication; for automatic proportioner use, a 50 g/L stock solution is diluted at 1:100 to 1:200. Terminal product types include 20% w/w water-soluble granules, 0.1% w/v oral solution in 1 L bottles, and 100 g sachets for direct header-tank addition.

When Injectable-Grade Solutions Require Pyrogen Reduction Ahead of Sterile Filtration

Preparation of a sterile parenteral from the powder begins with depyrogenation, because the raw herbal matrix carries bacterial endotoxin loads that can exceed the 0.5 EU/mL limit for parenteral products unless removed. The applicable compliance framework is EU GMP Annex 1 for manufacture of sterile medicinal products, with in-process controls per Ph. Eur. 2.9.19 for sub-visible particles, Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 5.1.1 for sterility, and 21 CFR 211.167 for final testing in the United States. In the preparation process, the powder is dissolved at 0.10 g/mL in water for injection preheated to 35–40°C, adjusted to pH 6.5–7.5 with 1 M sodium hydroxide or hydrochloric acid, and treated with 0.05% w/v activated carbon at 60°C for 30 min under continuous agitation. The mixture is cooled to 25°C, clarified through 0.45 µm polypropylene prefilters, and sterilized through 0.22 µm PVDF filters before filling into 10 mL amber glass ampoules or 50 mL vials under Grade A laminar airflow. Terminal sterilization at 121°C for 15 min is selected only where thermal stability data demonstrate no loss of marker compounds; otherwise, the entire filling line must be validated as aseptic. The addition ratio may also be expressed in dry-matter terms: for every 1 L of injectable solution, 100 g of input powder is used before carbon clarification, and the final filtrate volume is adjusted by assay to the registered content. Terminal product types include 10 mL ampoules, 20 mL vials, and 100 mL multidose vials where the preservative system has been validated.

Within neonatal calf units where cryptosporidiosis and rotavirus co-infection produce dehydration and febrile morbidity, the powder is processed into oral drench packs or rapidly dispersible tablets for use alongside electrolyte therapy. This application route is dominated by oral solid handling constraints rather than sterility, but downstream manufacturers still operate under VICH GL18 residual solvent guidance, Ph. Eur. 2.9.3 described dissolution testing, and the Chinese Veterinary Pharmacopoeia 2020 monographs for the component herbs; where the product is registered in the European Union, Regulation (EU) 2019/6 Article 8 pharmaceutical quality documentation applies. The addition ratio for oral drenching is calculated at 0.5–1.0 g of powder per 10 kg body weight twice daily, mixed into 250 mL of electrolyte solution immediately before administration; tablets are dry-blended at 200 mg input powder per 2 g total tablet mass. The downstream production route uses wet granulation to avoid segregation of the high-fine fraction: the powder is premixed with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and a 5% w/w PVP K30 binder dispersion, wet-milled through a 1.2 mm screen, and dried in a fluid-bed dryer at 50–55°C until moisture content is 2.5–3.5%. After dry milling and lubrication with 0.5% w/w magnesium stearate, the granulate is compressed on a 16-station rotary tablet press with 10 kN compression force in a 25% RH environment because higher humidity activates capping and lamination in hygroscopic botanical granulates. Terminal product types include 2 g oral tablets, 25 g oral drench sachets, and 500 g pack units for nasogastric administration in veterinary hospitals.

Capsule Fill Weight Drift Under Elevated Humidity Loads

Capsule filling of the milled powder on semi-automatic machines in companion-animal GMP facilities is sensitive to the glass transition and moisture equilibrium of the dried extract. The powder gains moisture rapidly above 60% RH, causing bridging in hopper augers and fill-weight drift beyond ±5%; this field-documented failure mode is observed when 200 mg capsule targets are run for more than 4 h in an uncontrolled cleanroom. Compliance for this route is derived from Ph. Eur. 2.9.40 uniformity of dosage units, Ph. Eur. 2.2.8 water content by Karl Fischer, and the national veterinary medicine GMP rules applicable to non-sterile solid oral dosage forms; when the capsules are compounded as extemporaneous preparations, USP <795> sets beyond-use dating and environmental monitoring expectations. For a 10 kg canine patient, the addition ratio is 150–300 mg of powder per day, divided into two equal capsule doses; the assembled capsule formulation consists of 200 mg active powder, 40 mg microcrystalline cellulose, 10 mg colloidal silicon dioxide, and a hard gelatin capsule shell of size 3. The production sequence includes blending in a 5 L V-blender for 15 min, encapsulation at 20–25°C and ≤40% RH, and metal detection with 1.0 mm ferrous, 1.5 mm non-ferrous, and 2.0 mm stainless-steel thresholds. Terminal product types include 200 mg hard gelatin capsules in 30-count blister packs and 250 mg capsules in 100-count HDPE bottles with desiccant.

Medicated Feed Premix Homogeneity and Carryover Thresholds in Integrated Mills

A vertically integrated feed mill requires a premix that can survive pneumatic conveying, batch-to-batch carryover in drag conveyors, and dilution into final feed at the correct legal inclusion rate. The dominant process conflict is that the powder’s hydrophobic flavonoid fraction adheres to steel surfaces at low moisture, while the polysaccharide fraction becomes tacky above 65% RH, increasing residue and cross-contamination. The governing compliance documents are Regulation (EU) 2019/4 on medicated feed, 21 CFR Part 225 current good manufacturing practice for medicated feeds in the United States, and the ASEAN guidelines on good manufacturing practices for medicated feed where applicable. Addition ratios in finished feed are set as a weight-by-weight percentage: a 0.5% w/w premix is diluted at 2.0 kg premix per 1000 kg complete feed to achieve the intended dose, and a 5.0% w/w micro-ingredient premix is used at 0.2 kg/tonne in precision proportioners. Mixing is carried out in a horizontal double-ribbon blender of 2000 kg capacity with a 12 min main blend time and a 3 min cut-in of the premix; homogeneity testing on 10 samplings per batch must yield a coefficient of variation below 5.0% using a validated marker or near-infrared method. The final product line includes 25 kg multi-wall paper bags with polyethylene liner, 1 tonne bulk bags for direct mill use, and 0.5% w/w premix for feed integrators.